Cannabidiol (CBD) and tetrahydrocannabinol (THC) have been under investigation for their potential to provide relief for individuals with Multiple Sclerosis (MS). These compounds have sparked interest due to their diverse therapeutic properties. CBD, recognized for its anti-inflammatory characteristics and neuroprotective potential, is being explored for its ability to address the inflammation within the central nervous system that contributes to the progression of MS. Simultaneously, THC, known for its analgesic effects, shows promise in alleviating MS-related pain and muscle spasms. Additionally, both cannabinoids exhibit the potential to modulate the immune system, which could help in mitigating the immune response involved in attacking the myelin sheath, the protective layer surrounding nerve fibers in MS patients. Studies and anecdotal evidence suggest that cannabis-derived medications containing CBD and THC, like Sativex, may assist in managing symptoms such as spasticity and neuropathic pain in MS patients.